SeaTown Holdings Pte. Ltd. acquired a new position in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 64,000 shares of the company’s stock, valued at approximately $7,948,000. SeaTown Holdings Pte. Ltd. owned about 0.06% of Guardant Health as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. BlackRock Inc. boosted its stake in Guardant Health by 2.2% in the 2nd quarter. BlackRock Inc. now owns 5,525,679 shares of the company’s stock worth $686,235,000 after purchasing an additional 121,224 shares during the period. Fred Alger Management LLC increased its stake in Guardant Health by 27.4% in the 1st quarter. Fred Alger Management LLC now owns 2,637,489 shares of the company’s stock worth $402,613,000 after purchasing an additional 567,042 shares during the period. Nuveen Asset Management LLC increased its stake in Guardant Health by 11.7% in the 1st quarter. Nuveen Asset Management LLC now owns 2,308,652 shares of the company’s stock worth $352,416,000 after purchasing an additional 242,682 shares during the period. Coatue Management LLC increased its stake in shares of Guardant Health by 80.5% during the first quarter. Coatue Management LLC now owns 2,018,453 shares of the company’s stock valued at $308,117,000 after buying an additional 899,916 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Guardant Health by 11.8% during the first quarter. Franklin Resources Inc. now owns 1,811,191 shares of the company’s stock valued at $276,478,000 after buying an additional 191,472 shares during the period. Institutional investors and hedge funds own 87.58% of the company’s stock.
Guardant Health stock traded down $2.33 during midday trading on Thursday, hitting $128.94. 1,154 shares of the company were exchanged, compared to its average volume of 951,372. The company has a debt-to-equity ratio of 1.44, a quick ratio of 19.30 and a current ratio of 19.57. The firm has a market capitalization of $13.06 billion, a PE ratio of -34.82 and a beta of 0.51. The business has a fifty day simple moving average of $117.65 and a two-hundred day simple moving average of $128.73. Guardant Health, Inc. has a fifty-two week low of $96.66 and a fifty-two week high of $181.07.
In related news, Director Stanley J. Meresman sold 4,934 shares of the firm’s stock in a transaction dated Monday, July 12th. The stock was sold at an average price of $124.27, for a total transaction of $613,148.18. Following the transaction, the director now owns 8,993 shares of the company’s stock, valued at $1,117,560.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ian T. Clark sold 10,559 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 29th. The shares were sold at an average price of $130.00, for a total transaction of $1,372,670.00. Following the sale, the director now owns 5,719 shares of the company’s stock, valued at $743,470. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,361 shares of company stock worth $3,190,158. Insiders own 5.80% of the company’s stock.
A number of research firms have recently weighed in on GH. Raymond James began coverage on shares of Guardant Health in a research report on Tuesday, June 15th. They issued a “market perform” rating on the stock. The Goldman Sachs Group began coverage on shares of Guardant Health in a research note on Thursday, June 3rd. They set a “buy” rating and a $160.00 target price on the stock. Wells Fargo & Company upped their target price on shares of Guardant Health from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, June 21st. Zacks Investment Research raised shares of Guardant Health from a “sell” rating to a “hold” rating in a research report on Monday, August 16th. Finally, William Blair reissued a “buy” rating on shares of Guardant Health in a report on Thursday, May 27th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $164.00.
Guardant Health Profile
Guardant Health, Inc is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.
Featured Story: What is a stock buyback?
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.